Clinical trial tests drug combination in mesothelioma of the lung or abdomen
Patients with pleural (lung) or peritoneal (abdominal) mesothelioma may be eligible to participate in a new clinical trial at the NIH Clinical Center.
Mesothelioma is an aggressive form of cancer caused by asbestos. When asbestos fibers are inhaled, mesothelioma can take hold in the lining of the lungs (the pleura). When fibers are ingested, the disease can form in the lining of the abdomen (the peritoneum). Mesothelioma has no known cure and a very poor prognosis. Raffit Hassan, M.D., of the Thoracic and GI Malignancies Branch is leading a study to determine a safe dose of LMB-100 and SEL-110 in patients with advanced mesothelioma. LMB-100 is a synthetic protein that binds to the mesothelin protein on tumors, which allows the drug to attack and kill tumor cells. However, the body sometimes creates antibodies that attack LMB-100 and reduce its effectiveness. Investigators hope that adding SEL-110 will prevent these drug-blocking antibodies from developing.
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.05/2018